MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
https://doi.org/10.20996/1819-6446-2014-10-4-432-437
Abstract
Prevention of thromboembolic complications in patients with atrial fibrillation during catheter pulmonary veins isolation is discussed. This subject review is presented with special consideration to new anticoagulants.
About the Authors
E. A. Belikov
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
K. V. Davtyan
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
O. N. Tkacheva
State Research Centre for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Petroverigsky per. 10, Moscow, 101990 Russia
References
1. RSSA guidelines for the VNOA electrophysiological studies, catheter ablation and implantable use of antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/Recomend2013.pdf. Accessed by 20.08.2014. Russian (Клинические рекомендации ВНОА по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. Доступно на: http://www.vnoa.ru/literature/Recomend2013.pdf. Проверено 20.08.2014).
2. Calkins H, Brugada J, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation ofAtrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. J Interv Card Electrophysiol 2012;33(2):171-257
3. Cappato R, Calkins Н, Chen S et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ arrhythm electrophysiol 2010;3:32-8.
4. Siklódy CH, Deneke Т, Hocini M et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol 2011;58(7):681-8.
5. Camm AJ, Lip G, De Caterina R et al. Atrial fibrillation (management of) 2010 and focused update (2012), ESC clinical practice guidelines. Eur Heart J 2012;33:2719-47.
6. Diagnosis and treatment of atrial fibrillation. 2012 RSC/RSSA/RACVS guideline. Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Accessed by 06.08.2014. Russian (Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, ВНОА, АССХ (2012). Доступно на: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 06.08.2014).
7. Pisters RI, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100.
8. Tapanainen JM, Braunschweig F, Schwieler J et.al. Сontinuous warfarin therapy is safe and feasible in catheter ablation of atrial fibrillation. Scand Cardiovasc J 2013;47(2):109-13.
9. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129(25):2638-44.
10. Heidbuchel H, Verhamme P, Alings M, et.al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34(27):2094-106.
11. Lakkireddy D, Reddy YM, Di Biase L, et.al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59(13):1168-74.
12. Winkle RA, Mead H, Engel G, et al. Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Ablation for Atrial Fibrillation. J Am Coll Cardiol 2012;60(12):1118-19.
13. Lakkireddy D, Reddy YM, Di Biase L et.al. Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial fibrillation results From a Multicenter Prospective Registry. J Am Coll Cardiol 2014;63(10):982-8.
14. Ren JF, Marchlinski F, Callans D, et al. Left atrial thrombus associated With ablation for atrial fibrillation: identification with intracardiac Echocardiography. J Am Coll Cardiol 2004;43(10):1861-7.
15. Shurrab M, Morillo С.A.Schulman S, et al. Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. Canadian Journal Of Cardiology 2013;29(10):1203-10.
16. Eitel С, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. EP Europace 2013;15(11):1587-93.
17. Ichiki H, Oketani N, Ishida S, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Pacing and Clinical Electrophysiology 2013;36(11):1328-35.
18. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available at: https://clinicaltrials.gov/ct2/show/NCT01729871?term=venture&rank=2. Accessed by 20.08.2014.
Review
For citations:
Belikov E.A., Davtyan K.V., Tkacheva O.N. MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology. 2014;10(4):432-437. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-4-432-437
Views:
711
Email this article 